戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1                   For ex vivo evaluation, 15 chylous and five nonchylous study participant fluid samp
2 on allows for noninvasive differentiation of chylous and nonchylous ascites and pleural effusions.
3  [95% CI: 74%, 100%]) for differentiation of chylous and nonchylous effusions.
4 on threshold was determined to differentiate chylous and nonchylous fluids.
5                                              Chylous ascites (CA) is an extremely rare complication a
6 umothorax (n = 3), chylous effusion (n = 1), chylous ascites (n = 3), complications from renal angiom
7 la (n = 2; 8%), and combined chylothorax and chylous ascites (n = 4; 16%).
8      Complications included one patient with chylous ascites and one with a prolonged air leak, both
9                                              Chylous ascites is a rare complication after donor nephr
10 t in valve defects that subsequently lead to chylous ascites or chylothorax.
11                                              Chylous ascites refers to the accumulation of lipid-rich
12 resenting as chylothorax, pleural effusions, chylous ascites, and lymphedema, is a severe disorder of
13 ion from blood, and their presence in urine, chylous ascites, and pleural effusions are consistent wi
14 edema, secondary lymphedema, chylothorax and chylous ascites, lymphatic malformations, and overgrowth
15 t with nonimmune fetal hydrops, chylothorax, chylous ascites, or lymphedema.
16 ficient mice, with subsequent development of chylous ascites.
17 lature, resulting in perinatal appearance of chylous ascites.
18 rmalities, extensive hepatocyte necrosis and chylous ascites.
19 s, but who was determined to actually have a chylous cyst, is described herein.
20                                              Chylous cysts of the neck or chest wall can be caused by
21 s (n = 4), native lung pneumothorax (n = 3), chylous effusion (n = 1), chylous ascites (n = 3), compl
22 ay via DCMRL in a patient with a symptomatic chylous effusion not previously assessed with current te
23                         Standard therapy for chylous effusion with the addition of pressure control v
24 eginning sirolimus therapy, 12 patients with chylous effusions and 11 patients with lymphangioleiomyo
25 f lung function and reduction in the size of chylous effusions and lymphangioleiomyomas in patients w
26 le and serious complications associated with chylous effusions are well known.
27          Materials and Methods Patients with chylous effusions evaluated from January 2014 and Decemb
28                      Background Diagnosis of chylous effusions normally requires invasive paracentesi
29 is characterized by cystic lung destruction, chylous effusions, lymphangioleiomyomas, and angiomyolip
30 tic intervention in patients with persistent chylous effusions.
31 atic interventions in patients with thoracic chylous effusions.
32                                              Chylous fistulas resolved in 5 to 16 days (mean time 12.
33 from 11 of 14 (79%) patients with AML and in chylous fluid from 1 of 3 (33%) patients.
34 lymphangiectasia, chylolymphatic reflux, and chylous leak.
35                                              Chylous leakage (CL) is a rare complication of laparosco
36 ic pathologic abnormalities causing thoracic chylous leakages before lymphatic intervention.
37 og, i.a.) abolished the afferent response to chylous lymph in 83% of these units.
38                                              Chylous lymph was significantly more potent than control
39 on of lipid (Intralipid, 170 micromol h(-1), chylous lymph) or a dextrose and/or electrolyte solution
40 de, 1 mg kg(-1), i.v.) significantly reduced chylous lymph-induced inhibition of gastric motility.
41 was increased by close-arterial injection of chylous lymph; devazepide (100 microg, i.a.) abolished t
42 ruary 2018, 29 study participants with known chylous (n = 17) and nonchylous (n = 12) effusions were
43                                              Chylous pleural effusion (chylothorax) frequently accomp
44 phatic involvement-thoracic duct dilatation, chylous pleural effusion, ascites, and LALM-is more comm
45 calcifications, and one patient with chronic chylous pleural effusion.
46             Conclusion MRI can help identify chylous versus nonchylous ascites and pleural effusions
47 int Dixon-derived fat fraction was higher in chylous versus nonchylous fluids (mean, 2.5% +/- 1.2 [st
48 n vivo studies, fat fraction was greater for chylous versus nonchylous fluids (mean, 6.2% +/- 4.3 vs